Neuropeptide Y polymorphism significantly magnifies diabetes and cardiovascular disease risk in obesity: the Hoorn Study

U. Jaakkola, J. Kallio, R.J. Heine, M.G.A.A.M. Nijpels, L.M. Hart, J.A. Maassen, L.M. Bouter, C.D.A. Stehouwer, J.M. Dekker

Research output: Contribution to JournalArticleAcademicpeer-review

163 Downloads (Pure)

Abstract

The leucine7 to proline7 (Leu7Pro) polymorphism in preproneuropeptide Y (preproNPY) has been associated with accelerated atherosclerosis and type II diabetes, both of which are obesity-related diseases. The current study evaluated the impact of obesity on the disease risk linked to the Leu7Pro polymorphism of preproNPY in 393 elderly subjects. In 6 years follow-up, the polymorphism alone did not change the risk for abnormal glucose regulation, while obesity was associated with a significant 3-fold risk (odds ratio (OR) 2.95; 95% confidence interval (CI) 1.81-4.81, P<0.001) and the Leu7Pro polymorphism-obesity interaction, with a remarkable 12-fold risk (OR 12.33; 95% CI 1.18-128.35, P<0.05). The Leu7Pro polymorphism modified significantly the 10-year incidence of cardiovascular events, causing a 7.6-fold increase in the hazard ratio (HR 7.58; 95% CI 2.87-20.03, P<0.001) in the obese but not in the nonobese subjects. The results indicate that obesity may be a pivotal factor in multiplying the disease risk associated with the Leu7Pro polymorphism in preproNPY
Original languageEnglish
Pages (from-to)150-152
Number of pages3
JournalEuropean Journal of Clinical Nutrition
Volume63
Issue number1
DOIs
Publication statusPublished - 2009

Bibliographical note

DA - 20090107 LA - eng JT - European journal of clinical nutrition

Fingerprint Dive into the research topics of 'Neuropeptide Y polymorphism significantly magnifies diabetes and cardiovascular disease risk in obesity: the Hoorn Study'. Together they form a unique fingerprint.

Cite this